# Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

> **NCT04269889** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 15 (actual)

## Conditions studied

- Anemia, Diamond-Blackfan

## Interventions

- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT04269889
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2022-08-16
- **Final completion:** 2024-02-16
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04269889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04269889, "Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04269889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*